Rachel Kerr
- Oncology top 0.5%
- Colorectal Cancer Treatments and Studies 70
- Colorectal Cancer Surgical Treatments 28
- Cancer Treatment and Pharmacology 22
- Pathology and Forensic Medicine top 0.5%
- Genetic factors in colorectal cancer 44
- Cancer Research top 2%
- Cancer Genomics and Diagnostics 9
- Biotechnology top 2%
- Cancer Research and Treatments 15
- Hepatology top 5%
-
- Gastric Cancer Management and Outcomes 15
-
- Virus-based gene therapy research 12
- Co-authors
- Rachel MidgleyLawrence S. YoungIan TomlinsonElaine JohnstoneAxel WaltherCharles SwantonDavid A. AndersonAristides G. Eliopoulos
- Journals
- New England Journal of Medicine (1 paper)The Lancet (4 papers)Journal of Clinical Oncology (21 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
Rachel Kerr
143 papers receiving 6.3k citations
Hit Papers
Peers
Comparison fields: 5 of 159
- Oncology 3.3k
- Pathology and Forensic Medicine 1.3k
- Cancer Research 987
- Biotechnology 325
- Hepatology 278
Countries citing papers authored by Rachel Kerr
This map shows the geographic impact of Rachel Kerr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel Kerr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel Kerr more than expected).
Fields of papers citing papers by Rachel Kerr
This network shows the impact of papers produced by Rachel Kerr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel Kerr. The network helps show where Rachel Kerr may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Rachel Kerr, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 3 | |
| 3 | COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study | 2020 | 4 |
| 4 | 2020 | 17 | |
| 5 | 2019 | 6 | |
| 6 | 2018 | 13 | |
| 7 | 2016 | 6 | |
| 8 | 2010 | 9 | |
| 9 | 2009 | 343 | |
| 10 | 2008 | 235 | |
| 11 | 2007 | 43 | |
| 12 | 2005 | 69 | |
| 13 | 2005 | 75 | |
| 14 | 2003 | 80 | |
| 15 | Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials. | 2002 | 10 |
| 16 | 2002 | 1 | |
| 17 | 2000 | 1 | |
| 18 | 2000 | 63 | |
| 19 | Virus-directed enzyme prodrug therapy using retrovirally delivered E. coli nitroreductase and CB1954 | 1998 | 2 |
| 20 | 1991 | 8 |
About Rachel Kerr
Rachel Kerr is a scholar working on Oncology, Pathology and Forensic Medicine and Biotechnology, having authored 153 papers that have together received 6.5k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (70 papers), Genetic factors in colorectal cancer (44 papers), Colorectal Cancer Surgical Treatments (28 papers), Cancer Treatment and Pharmacology (22 papers), Gastric Cancer Management and Outcomes (15 papers), Cancer Research and Treatments (15 papers), Virus-based gene therapy research (12 papers) and Cancer Genomics and Diagnostics (9 papers). The work is most often cited by research in Oncology (3.3k citations), Pathology and Forensic Medicine (1.3k citations) and Cancer Research (987 citations). Rachel Kerr has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Rachel Midgley, Lawrence S. Young, Ian Tomlinson, Elaine Johnstone, Axel Walther, Charles Swanton, David A. Anderson, Aristides G. Eliopoulos, J. Herod and D. Fyfe. Their work appears in journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.